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N6-Methyladenosine (m6A), the most abundant posttranscriptional messenger RNA (mRNA) 45 
modification, is emerging as an important regulator of gene expression1. Manipulation of m6A 46 
impacts different developmental and biological processes, and altered m6A homeostasis is 47 
linked to cancer2-5. m6A is catalyzed by METTL3 and enriched in the 3’ untranslated region (3’ 48 
UTR) of a large subset of mRNAs at sites close to the stop codon1. METTL3 can promote 49 
translation but the mechanism and widespread relevance remain unknown2. Here we show that 50 
METTL3 enhances translation only when tethered to reporter mRNA at sites close to the stop 51 
codon supporting a mRNA looping mechanism for ribosome recycling and translational 52 
control. Electron microscopy reveals the topology of individual polyribosomes with single 53 
METTL3 foci found in close proximity to 5’ cap-binding proteins. We identify a direct physical 54 
and functional interaction between METTL3 and the eukaryotic translation initiation factor 3 55 
subunit h (eIF3h). METTL3 promotes translation of a large subset of oncogenic mRNAs, 56 
including Bromodomain-containing protein 4 (BRD4) that are also m6A-modified in human 57 
primary lung tumors. The METTL3-eIF3h interaction is required for enhanced translation, 58 
formation of densely packed polyribosomes, and oncogenic transformation. METTL3 depletion 59 
inhibits tumorigenicity and sensitizes lung cancer cells to BRD4 inhibition. These findings 60 
uncover a mRNA looping mechanism of translation control and identify METTL3-eIF3h as a 61 
potential cancer therapeutic target. 62 
 63 
Despite a growing awareness of the biological importance of m6A in various organisms, the 64 
mechanisms for how m6A regulates gene expression remain poorly understood. YTH-domain 65 
containing proteins can specifically bind m6A-modified RNA to regulate mRNA splicing, export, 66 
stability, and translation1,6-8. In addition, we found that METTL3 itself can promote the translation of 67 
oncogenes including EGFR in human lung cancer cells2. However, the molecular mechanism and the 68 
functional relevance of METTL3 in translation remain unclear. 69 
 70 
 71 
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The initiation step of translation is rate limiting and a closed-loop model was proposed to 72 
facilitate multiple rounds of mRNA translation. This is supported by functional and physical interaction 73 
between the capped 5’ terminus and the polyadenylated 3’ terminus of mRNA mediated by translation 74 
initiation factor eIF4G and PABPC1 (poly(A) binding protein cytoplasmic 1)9-12. Our functional and 75 
structural data support an alternative closed loop model, where circularization of the mRNA is 76 
mediated by association between the eIF3h subunit at the 5’-end of the mRNA and METTL3 bound to 77 
specific sites near the translation stop codon. We find that METTL3 promotes translation of a large 78 
subset of oncogenic mRNAs and that METTL3-eIF3h interaction is required for oncogenic 79 
transformation. These findings provide new insights into the mechanism of translation control and 80 
suggest that METTL3-eIF3h and downstream oncogenes could be therapeutic targets for cancer. 81 
 82 
To test a mRNA looping model we first examined whether the METTL3 binding position on 83 
mRNA is important for its ability to enhance translation. Using reporters with MS2 binding sites 84 
located at different positions (Extended Data Fig. 1a) we found that direct METTL3 tethering can 85 
promote translation only when bound to the 3’ UTR at a position near the stop codon. In vitro 86 
translation assays performed with lystates from human cells or rabbit reticulocytes, recombinant 87 
METTL3 protein, and in vitro transcribed mRNAs confirmed that full-length METTL3 or an amino-88 
terminal fragment (1-200 aa) that is sufficient to promote reporter translation in cells (Extended Data 89 
Fig. 2), enhanced translation of a luciferase reporter mRNA (Extended Data Fig. 1e-g). METTL3 90 
tethering had a stronger affect on mRNAs without a poly (A) tail (Extended Data Fig. 1g), which is 91 
consistent with some redundancy between METTL3 and eIF4G-PABPC1-mediated looping for poly 92 
(A)-containing mRNAs in these in vitro assays.  93 
 94 
To provide evidence that METTL3 is bound to polyribosomes FLAG-METTL3-containing 95 
mRNA ribonucleoprotein complexes (mRNPs) were affinity purified, incubated with α-METTL3 gold-96 
labeled antibodies, subjected to sucrose gradient fractionation, and then analyzed by electron 97 
microscopy (EM) (Fig. 1a). This revealed gold-labeled METTL3 in the individual polyribosomes 98 
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(Extended Data Fig. 4a, b). We performed similar experiments using either α-CBP80 or α-eIF4E gold-99 
labeled antibodies together with the α-METTL3 particles. Since the α-CBP80 and α-eIF4E gold 100 
particles were larger they could be distinguished from the α-METTL3 particles. Individual 101 
polyribosomes containing double-labeled gold particles showed that each METTL3 signal is in close 102 
proximity (<20 nm) to a cap-binding protein (Fig. 1b and Extended Data Fig. 4c, d). This reveals the 103 
topology of individual endogenous METTL3-bound polyribosomes and support that METTL3 mediates 104 
the looping of mRNA to promote efficient translation. 105 
 106 
Full length METTL3 as well as the 1-200 aa, and 1-350 aa fragments were found to associate 107 
with m7GTP-Agarose in cap-binding assays (Extended Data Fig. 3a). This result is highly consistent 108 
with tethering assays (Extended Data Fig. 2) and support that the 1-200 aa fragment of METTL3 109 
interacts with translation initiation factor(s) to promote translation. Knockdown of METTL3 had no 110 
significant effect on the association of cap-binding proteins or translation initiation factors (Extended 111 
Data Fig. 3b). This result indicates translation initiation complex formation does not require METTL3. 112 
Conversely, the association of METTL3 with m7GTP-Agarose was dramatically diminished using 113 
lysates depleted for CTIF, eIF4GI or eIF3b, supporting that the association of METTL3 with m7GTP-114 
Agarose is mediated through a physical interaction with general translation initiation factor(s) 115 
(Extended Data Fig. 3c).  116 
 117 
A large-scale purification and mass spectroscopy characterization of FLAG-METTL3-118 
containing complexes identified numerous translation factors (Extended Data Fig. 3d, and data not 119 
shown). Gene ontology (GO) analysis of the METTL3-interacting proteins identified ‘mRNA metabolic 120 
processes’, ‘RNA processing’, and ‘Translation’ as the most significantly enriched categories 121 
(Extended Data Fig. 3e, f). Considering this and our previous observation that METTL3 knockdown 122 
diminishes the association of eIF3 with cap-binding proteins in co-IP experiments, we hypothesized 123 
that METTL3 might interact directly with certain component(s) of the multi-subunit eIF3 complex. 124 
 125 
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 To test whether METTL3 interacts with any of the 13 subunit(s) of eIF3. Recombinant METTL3 126 
and 1-200 aa were used in a Far-Western blotting assay with a biochemically isolated human eIF3 127 
complex (Extended Data Fig. 4e and Fig. 1c). METTL3 and 1-200 aa both specifically bound to a 128 
single band that based on size most likely corresponds to eIF3g, -h, -i, -j, or -m (Fig. 1d). To further 129 
confirm this interaction and to define the particular subunit(s) that interacts with METTL3, we 130 
individually expressed and purified each of the GST-tagged eIF3 subunits from bacteria (Extended 131 
Data Fig. 4f) and tested them for binding to His-METTL3 using in vitro binding assays with either His-132 
METTL3 or 1-200 aa. METTL3 (and 1-200 aa) were found to specifically interact with eIF3h (Fig. 1e). 133 
The interaction between eIF3h with METTL3 was further confirmed using a α-METTL3 antibody (that 134 
recognizes a 1-250 aa METTL3 epitope) to specifically disrupt this eiF3h-METTL3 interaction 135 
(Extended Data Fig. 4g). Additional GST pull-down experiments identified the Mpr1p/Pad1p N-136 
terminal (MPN) domain13 as necessary and sufficient to interact with METTL3 (Extended Data Fig. 4h-137 
j). It is noteworthy that the MPN domain faces the solvent side of the ribosome that is likely accessible 138 
for interaction with METTL3 without impairing 80S assembly13.  139 
 140 
An in situ proximity ligation assay (PLA) confirmed METTL3-eIF3h proximity in cells (Fig. 1f). 141 
co-IP experiments revealed that METTL3 association with translation initiation factors is dependent on 142 
eIF3h (Fig. 1g).  We next tested the functional interaction between METTL3 and eIF3h, and found 143 
depletion of eIF3h abrogated the enhanced reporter translation by METTL3 (Extended Data Fig. 4k-m 144 
and Fig. 1h). Overall, our results support a model whereby mRNA circularization and translation 145 
control is mediated by a specific METTL3-eIF3h interaction (Fig. 1i).  146 
  147 
We next examined the widespread impact of METTL3 on mRNA translation (Fig. 2, and 148 
Extended Data Fig. 5a). METTL3 depletion caused an increase in the 80S ribosome peak and a 149 
corresponding reduction of polyribosome peak (Fig. 2a). METTL3 depletion had a negligible effect on 150 
steady state mRNA abundance whereas translation efficiency of a large subset (4,267) of mRNAs 151 
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was reduced by at least 2-fold in METTL3-depleted cells (Fig. 2b-d). Comparison of these genes with 152 
previously reported METTL3 PAR-CLIP data14 identified 809 mRNAs that are both bound and 153 
translationally regulated by METTL3 (Fig. 2d). Interestingly, mRNAs on this list of METTL3 target 154 
mRNAs have on average longer 3’ UTRs compared to all mRNAs (Fig. 2e). Gene ontology (GO) 155 
showed that these mRNAs are involved in tumor progression and apoptosis (Extended Data Fig. 5b). 156 
qRT-PCR analysis confirmed that METTL3 depletion had a modest effect on individual target mRNA 157 
abundance (Extended Data Fig. 5c), but strongly decreased translation of target mRNAs (Fig. 2f). 158 
Moreover, neither global mRNA stability analysis by RNA-seq (Fig. 2g) nor qRT-PCR analysis of 159 
individual genes (Extended Data Fig. 5d, e) showed any significant differences in mRNA stability upon 160 
METTL3 depletion. We isolated endogenous METTL3 mRNPs and confirmed the associated of target 161 
mRNAs by qRT-PCR (Fig. 2h and Extended Data Fig. 6a). Western blotting showed decreased 162 
protein expression from these target mRNAs in the METTL3 knockdown samples (Fig. 2i), whereas 163 
analysis of mRNA sequencing data revealed that the splicing patterns of these target mRNAs was 164 
unaltered in METTL3 depleted cells (Extended Data Fig. 6). Depletion of YTHDF1, a m6A-reader 165 
protein implicated in translational control had no effect on the expression of these METTL3 targets 166 
(Extended Data Fig. 6c)7. Western blotting showed strongly reduced endogenous BRD4 protein 167 
expression upon knockdown of eIF3h without affecting BRD4 mRNA abundance or the levels of 168 
METTL3 protein (Fig. 2j and Extended Data Fig. 6d). Expression of a shRNA-resistant FLAG-METTL3 169 
rescued the expression of BRD4 and CD9 proteins. However, expression of a catalytic mutant of 170 
METTL3 failed to recover the protein expression of target genes (Fig. 2k). METTL3 knockdown in 171 
A549 lung cancer cells similarly led to decreased expression of BRD4 and other targets (Fig. 2l), and 172 
treatment of METTL3-depleted and control- A549 cells with the BRD4 inhibitor JQ1 revealed that the 173 
METTL3 depleted cells are more sensitive to pharmacological BRD4 inhibition (Fig. 2m, n and 174 
Extended Data Fig. 6e). 175 
 176 
 Considering that 1-200 aa is sufficient to directly interact with eIF3h (Fig. 1 and Extended Data 177 
Fig. 4) and that 1-200 aa can promote translation in tethering experiments whereas 1-150 aa does not 178 
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(Extended Data Fig. 2), we reasoned that a region between 150-200 aa must be important for the 179 
physical and functional METTL3-eIF3h interaction. Secondary structure predictions identified a 180 
putative alpha helix (150-161 aa) within this region that is highly conserved in mammals (Extended 181 
Data Fig. 7a, b)15,16. Moreover, 3D modeling identified a putative structured module (Extended Data 182 
Fig. 7c)17. We therefore generated a mutant version of METTL3 with a single aa substitution of a 183 
highly conserved Alanine (A155P) to disrupt this putative helical structure. co-IP confirmed 184 
substantially impaired interaction of A155P with translation initiation factors specifically in RNase-185 
treated samples (Fig. 3a). Importantly, the A155P mutation did not disrupt METTL3 interaction with 186 
METTL14 (Fig. 3a). Tethering experiments demonstrated that the A155P mutant is strongly impaired 187 
in promoting mRNA translation (Fig. 3b and Extended Data Fig. 7d, e). Moreover, expression of 188 
METTL3 A155P in METTL3-depleted cells failed to rescue the expression of endogenous target 189 
proteins (Fig. 3c). This effect was not due to altered mRNA association of A155P with endogenous 190 
target mRNAs (Fig. 3d and Extended Data Fig. 7f). In summary, while METTL3 A155P mutant can 191 
associate with METTL14 and be loaded on mRNAs, its ability to interact with initiation factors and 192 
promote mRNA translation is severely compromised.  193 
 194 
 We next used in vitro reconstituted translation assays to explore the effect of 3’ UTR-bound 195 
METTL3 on translation efficiency and polysome conformation (Fig. 3e-f, Extended Data Fig. 7g and 196 
Extended Data Fig. 9a). Consistent with Extended Data Fig. 1g, tethering of recombinant METTL3 197 
increased translation efficiency with a stronger effect on mRNA without a poly (A) tail (Fig. 3e). In 198 
contrast, tethered A155P had no significant effect on translation (Fig. 3e). EM analysis of samples 199 
from the in vitro translation reactions showed mostly densely packed polysome structures formed 200 
when METTL3 was tethered to reporter mRNAs without a poly (A) tail (Extended Data Fig. 9a). In 201 
contrast, almost all the polysomes observed in the A155P sample appeared as linear polysomes (as 202 
in the control sample). Only dispersed ribosomes were observed in reactions without mRNA (Fig. 3f 203 
and Extended Data Fig. 9a). In all samples with poly (A)+ containing mRNAs mostly packed 204 
polysomes were observed irrespective of the protein that was tethered. Since the reporter mRNA 205 
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contains a very short 3’UTR it expected that the known eIF4GI-PABP interaction is likely responsible 206 
for observed packed polysomes in poly (A)+ samples (Fig. 3f and Extended Data Fig. 9a). We further 207 
analyzed in vitro translation assays by sucrose gradient fractionation. Tethering of WT METTL3 208 
tethering resulted in a larger polysome peak compared to the A155P mutant (Fig. 3g). Individual 209 
polysomes were analyzed by EM (Fig. 3g, h). Polysomes formed with WT METTL3 appeared more 210 
densely packed compared to the more linear polysomes that formed with the A155P mutant or MS2 211 
control (Fig. 3h). Taken together, these results strongly support our model that METTL3 through its 212 
interaction with eIF3h promotes translation through its effects on polysome conformation. 213 
 214 
 Considering that METTL3 regulates the translation of a large subset of genes that are involved 215 
in tumor progression and apoptosis (Extended Data Fig. 5b), we examined the role of METTL3 in 216 
cancer. Immunohistochemistry (IHC) staining of primary human lung adenocarcinoma samples and 217 
adjacent normal control tissue revealed that METTL3 expression is significantly increased in lung 218 
tumors and correlates with tumor stage (Fig. 4a, b and Extended Data Fig. 8a). METTL3 depletion in 219 
A549 lung cancer cells resulted in significantly smaller tumors in mouse xenografts (Fig. 4c and 220 
Extended Data Fig. 8b-d). 221 
 222 
We next examined the relevance of the METTL3-eIF3h interaction and mRNA looping in the 223 
context of cancer cell biology. Knockdown of eIF3h suppressed the ability of METTL3 to promote 224 
cellular invasion (Fig. 4d and Extended Data Fig. 8e). Moreover, unlike WT METTL3 protein, 225 
expression of either a catalytically inactive mutant, or the A155P mutant form was unable to promote 226 
the invasive capability of lung fibroblasts (Fig. 4e and Extended Data Fig. 8f). Furthermore, METTL3 227 
overexpression was sufficient to promote the oncogenic transformation of NIH-3T3 cells, mouse 228 
embryonic fibroblasts (MEFs) or MB352 (p53 null MEFs) cells, whereas METTL3 A155P had no 229 
significant affect in these 3D soft agar colony formation assays (Fig. 4f-h and Extended Data Fig. 8g-230 
h). The oncogenic function of METTL3 was also studied in the mouse xenografts. NIH-3T3 cells with 231 
ectopic expression of METTL3 WT, METTL3 A155P, or the empty vector control were injected into 232 
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nude mice to determine their in vivo tumorigenic capacities. METTL3 WT overexpression promoted in 233 
vivo tumor growth, whereas METTL3 A155P showed an impaired ability to promote tumor growth. As 234 
control, no tumors were detected in mice injected with control NIH-3T3 cells (Fig. 4i and Extended 235 
Data Fig. 8i). Overall, these results support that the METTL3-eIF3h mediated mRNA looping is critical 236 
for the oncogenic function of METTL3. 237 
 238 
 meRIP-seq performed on four primary human lung tumors identified patient specific and 239 
commonly m6A-modified mRNAs in lung cancer (Extended Data Fig. 8j and Table S3). An expected 240 
“GGAC” motif was identified and m6A peaks are predominantly localized near the translation stop 241 
codon (Fig. 4j-k and Extended Data Fig. 8k). Gene ontology analysis revealed that the common 242 
methylated genes are enriched in the signature genes of neoplasms and cancer, including the known 243 
oncogenes EGFR and BRD4 (Fig. 4l and Extended Data Fig. 9b). These data were consistent with 244 
m6A features identified in cell lines, with >50% of the peaks found in both tumors and cancer cell lines 245 
(Extended Data Fig. 9c). 246 
 247 
 We propose that METTL3 promotes oncogene translation and tumorigenesis through a mRNA 248 
looping mechanism. This is supported by; 1) the position-dependent effects of METTL3 tethering on 249 
mRNA translation, 2) EM visualization of METTL3 bound to endogenous polyribosomes and its 250 
proximity to cap-binding proteins, 3) METTL3 interaction with eIF3h, and 4) Disruption of METTL3-251 
eIF3h interaction abolishes the ability of METTL3 to promote translation, affect polysome 252 
conformation, or promote oncogenic transformation. This METTL3-eIF3h loop presumably promotes 253 
translation through ribosome recycling in a way similar to that proposed for eIF4G-PABPC1-mediated 254 
mRNA looping. Indeed, while there is likely some redundancy between these mRNA circularization 255 
mechanisms, looping between the stop codon and the 5’ end might represent a more productive way 256 
to recycle ribosomes rather than via the 3’ end, especially for mRNAs with long 3’ UTRs since the 257 
ribosomes will dissociate from the mRNP once released at the stop codon. 258 
 259 
 10
 The complexity of eIF3 and the specialized roles of individual subunits is only beginning to be 260 
appreciated18,19. Imbalanced expression of eIF3 subunits is found in various tumors20 and expression 261 
in fibroblasts can promote malignant transformation21. Increased eIF3h expression has been found in 262 
different tumor types and in many cases is due to amplification of a region of chromosome 8 that 263 
includes the eIF3h gene at 8q23.3 and the nearby MYC oncogene22,23. METTL3 is overexpressed in 264 
many different cancer types (Extended Data Fig. 10a), and the expression of METTL3 and eIF3h is 265 
often positively correlated (Extended Data Fig. 10b, c). Our findings could pave the way for the 266 
development of new cancer therapeutic strategies. 267 
 268 
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 360 
Fig. 1 | METTL3 enhances translation of target mRNAs by interacting with eIF3h. a, Electron 361 
microscopy (EM) procedure. b, EM images of polyribosomes. Red arrows; METTL3 with immuno-gold 362 
particle (6 nm), yellow arrows; CBP80 with immuno-gold particle (10 nm). Three independently 363 
performed experiments show similar results. c-d, Far Western (FW). c, Staining of eIF3 complex. A 364 
breakdown product is denoted (∆eIF3a). Two independently performed experiments show similar 365 
results. d, FW of purified eIF3 complex. Two independently performed experiments show similar 366 
results.  e, GST pull-down assay. GST-tagged eIF3 subunits and co-purified His-METTL3 or 1-200 aa 367 
analyzed by Western blotting. Two independently performed experiments show similar results. f, 368 
Proximity ligation assay (PLA). Two independently performed experiments show similar results. g, Co-369 
IPs using lysates from control or eIF3h knockdown cells. Two independently performed experiments 370 
show similar results. h, Tethering assays. Error bars = mean ± SD; n = 3 biologically independent 371 
samples, two-sided t-test. i, Model. 372 
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 373 
Fig. 2 | METTL3 promotes translation of a large subset of mRNAs. a, Polysome profile. Two 374 
independently performed experiments show similar results.  b, Scatter plot of RNA-Seq data. Average 375 
read number from two individual METTL3 knockdowns is plotted. c, Scatter plot of translation 376 
efficiency (TE). Average read number from two shMETTL3 samples were calculated. d, Venn diagram 377 
showing tmRNAs with >2-fold change in TE and METTL3 PAR-CLIP data. e, Features of overlapping 378 
mRNAs (n=809) from (d) was compared with all (18,115) expressed genes. Error bars =mean ± SEM; 379 
unpaired t-test (two-sided). f, qRT-PCR analysis. Error bars =mean ± SD; n = 3 technical replicates. g, 380 
Box plot represents global mRNA (12,479 mRNAs) stability profiling from two biological replicates. 381 
Two-sided Wilcoxon rank sum test; the results are statistically not significant. h, qRT-PCR analysis of 382 
METTL3-associated mRNAs using two different αMETTL3 antibodies. Error bars =mean ± SD; n = 2 383 
independent experiments. i-l, Western blot. At least two independently performed experiments show 384 
similar results. m, MTS assay of A549 cellular proliferation upon JQ1 treatment. Error bars =mean ± 385 
SD; n = 3 independent experiments. Two-sided t-test, multiple comparison for the p-values; *** P < 386 
0.001, ** P < 0.01. n, Quantification of (sum of early and late) apoptotic cells. Error bars +mean ± SD; 387 
n = 3 independent experiments. Two-sided t-test, multiple comparison for the p-values; * p<0.05, 388 
**p<0.01. 389 
 390 
Fig. 3 | METTL3-eIF3h interaction is crucial for enhanced mRNA translation and polysome 391 
conformation. a, Co-IPs. Two independently performed experiments show similar results. b, 392 
Tethering assay. Error bars =mean ± SD; n = 6 independent experiments; two-sided t-test. c, Western 393 
blot. Two independently performed experiments show similar results.  d, qRT-PCR. Error bars =mean 394 
± SD; n = 2 independent experiments. e, In vitro translation of reporter mRNAs with Rabbit 395 
reticulocyte lysate. Error bars =mean ± SD; n = 6 independent experiments; two-sided t-test. f, 396 
Analysis of 20 images from each sample in (e). g, Peak analysis of polysome profiling coupled with in 397 
vitro translation. Two independently performed experiments show similar results.  h, EM images of 398 
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polyribosomes. Images were taken from the samples in (g). Scale bar, 50 nm. Two independently 399 
performed experiments show similar results.  400 
 401 
Fig. 4 | Role of METTL3 and m6A in lung cancer cells and primary human tumors. a-b, METTL3 402 
IHC in primary lung adenocarcinoma and adjacent normal control samples. a, Error bars =mean ± SD; 403 
n = 75; two-sided Wilcoxon signed-rank test. b, . Error bars =mean ± SD; Stage I, n =37; Stage II, n 404 
=18; Stage III, n =20; two-sided Wilcoxon signed-rank test. c, Tumor-growth of xenografts derived 405 
from A549 cells stably expressing indicated shRNAs. Error bars =mean ± SEM; n=5 independent 406 
mice. d-e, Quantification of invasive BJ cells. Cells were transiently transfected with indicated siRNAs 407 
(d) or plasmids (e). Error bars =mean ± SEM; n = 5 for (d), n = 9 for (e) independent experiments; 408 
two-sided t-test. f, Quantification of NIH-3T3 cells colony formation. Error bars =mean ± SEM; n = 3 409 
independent experiments; two-sided t-test; ns, not significant. g-h, Quantification of MEFs (g) or 410 
MB352 (h) cells colony formation. Error bars =mean ± SEM; n = 3 independent experiments; two-411 
sided t-test; ns, not significant. i, Tumor weight of xenografts derived from NIH-3T3 cells stably 412 
expressing indicated proteins. There was no tumor formation in empty vector group during the 413 
observed period. Error bars =mean ± SEM; n = 8 independent mice; two-sided t-test. j-l, Global 414 
profiling of m6A targets in primary lung cancer samples. j, Sequence motif identified in m6A MeRIP-415 
seq. k, Metagene analysis of m6A peaks. l, Integrative genomics viewer plots of representative m6A 416 
containing genes. Four lung tumors show similar results. 417 
 418 
Methods 419 
Cell Culture and transfection 420 
Human lung cancer cell lines (A549 and H1299), HEK293T, BJ, NIH-3T3, HeLa, MEFs were cultured 421 
with DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cells were grown in a 5% 422 
CO2 cell culture incubator at 37℃. Cell lines were authenticated with morphology, karyotyping, and 423 
PCR based approaches by ATCC. The cell lines were tested for potential mycoplasma contamination 424 
and confirmed that they are mycoplasma negative. Transfection of plasmids was performed using 425 
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Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Down regulation of 426 
target genes by siRNA was performed using Lipofectamine RNAi Max (Invitrogen). The following 427 
siRNA sequences were used in this study: 5′-r(GAUAGAUGGCCUUGUGGUA)(UU)-3′ for eIF3h-1; 5′-428 
r(GCGGAGCCUUCGCCAUGUA)(UU)-3′ for eIF3h-2; 5′-r(UGAGAAAGGAGGAGAGGAA)d(TT)-3′ for 429 
eIF4GI; 5′-r(UCAACCUCUUUACGGAUUU)d(TT)-3′ for eIF3b; and 5′-430 
r(GCAUCAACCUGAAUGACAU)(UU)-3′ for CTIF. 431 
 432 
Virus Production and generation of stable knockdown and over-expression cells 433 
Virus mediated generation of stable knockdown and over-expression cells were performed as 434 
described previously2. Briefly, shRNA containing pLKO.1 vector was co-transfected with pLP1, pLP2, 435 
and VSVG into 293T cells. For over-expression, pCDH vectors containing the METTL3 WT and A155436 
P cDNA were co-transfected with Delta 8.9 and VSVG plasmids into 293T cells. Viruses were 437 
collected at 48 hr and 72 hr after transfection and then used to infect cells with Polybrene (8 mg/ml, 438 
Sigma); 48 hr after infection, puromycin was added to the culture medium to select the infected cells.  439 
 440 
Plasmid construction 441 
pFLAG-METTL3 WT, pFLAG-MS2-METTL3 and pFLAG-MS2-METTL3 Mut, were described 442 
previously2. pFLAG-METTL3 A155P plasmids was generated by inducing point mutation in pFLAG-443 
METTL3 WT using Q5® Site-Directed Mutagenesis Kit (NEB E0554). Plasmids pFLAG-MS2-METTL3 444 
(1-100), pFLAG-MS2-METTL3 (1-150), pFLAG-MS2-METTL3 (1-200), pFLAG-MS2-METTL3 (1-350) 445 
and pFLAG-MS2-METTL3 (101-580) was constructed by substitution of PCR amplified each METTL3 446 
fragment into NotI-METTL3 WT-BglII site of pFLAG-MS2-METTL3. For stable METTL3 over-447 
expression, METTL3 WT and A155P sequence were PCR amplified and cloned into the NheI and 448 
NotI sites of pCDH-CMV-MCS-EF1-Puro plasmid. For expression of recombinant METTL3 proteins, 449 
METTL3 full length and N-terminal amino acids 1-200 cDNA were cloned into the pETDuet-1 and pET 450 
His6 GST TEV LIC cloning vector individually. For expression of recombinant METTL3 proteins for in 451 
vitro translation, FLAG-MS2, FLAG-MS2-METTL3 (1-200), FLAG-MS2-METTL3, FLAG-MS2-METTL3 452 
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A155P were cloned into pETDuet-1. For bacteria protein expression of human eIF3h, eIF3j and eIF3m 453 
that express N-terminal GST-fused proteins, BamHI/EcoRI fragment of pGEX2TK vector was ligated 454 
to the PCR amplified BamHI/EcoRI fragment that contained eIF3h, eIF3j, or eIF3m. In addition, for the 455 
pGEX2TK-eIF3g or -eIF3i, BglII/EcoRI fragment of pGEX2TK vector was ligated to the PCR amplified 456 
BglII/EcoRI fragment that contained either eIF3g or eIF3i, respectively. For bacteria expression of 457 
eIF3h deletion mutants were generated by ligation of BamHI/EcoRI fragment of pGEX2TK vector with 458 
BamHI/EcoRI fragment of either PCR amplified eIF3h (1-222) or eIF3h (29-222). The pGL3c_TK 459 
luciferase reporter (FLuc) and pGL3c_TK luciferase reporter containing 2X MS2 binding sites near the 460 
stop codon (FLuc-MS2bs) were described previously2. The 2X MS2 binding site sequence was PCR 461 
amplified from FLuc-MS2bs and inserted into the NcoI site of pGL3c_TK luciferase reporter to make 462 
the FLuc-5’UTR-MS2bs reporter that the MS2 binding sites are located in the 5’UTR region of 463 
luciferase gene. The 2X MS2 binding site sequence and GFP sequence (from CAG-GFP, Addgene 464 
Plasmid #16664) were cloned into the XbaI site of pGL3c_TK luciferase reporter (FLuc) to make the 465 
FLuc-MS2bs-GFP and FLuc-GFP-MS2bs reporters. For pFLAG-tethering effector plasmids, METTL3 466 
shRNA resistance plasmids were generated by introducing synonymous mutations in the shRNA 467 
targeting sequence using the Q5® Site-Directed Mutagenesis Kit (NEB E0554). All cloning primers 468 
are listed in Table S1. 469 
 470 
In vitro translation assay 471 
H1299 cells were harvested and resuspended in hypotonic buffer [10 mM Hepes (pH 7.4), 10 mM 472 
potassium acetate, 1.5 mM magnesium acetate, and 2.5 mM DTT]. Cells were then incubated on ice 473 
for 30min and ruptured by passing 10 times through a 25-gauge needle attached to a 3-mL syringe. 474 
The cell homogenate was centrifuged at 13,000 × g for 15 min at 4 °C. The supernatant was collected 475 
and used for in vitro translation. In vitro translation reactions were performed for 1 hour at 30°C using 476 
either H1299 cytoplasmic cell extracts or rabbit reticulocyte lysate (RRL) (Thermo FisherScientific, 477 
AM1200) in 20 µL reaction mixtures containing 100 ng of in vitro transcribed reporter mRNAs and 500 478 
ng of either purified recombinant His-FLAG-MS2, His-FLAG-MS2-METTL3 or His-FLAG-MS2-479 
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METTL3 (1-200) protein. The activity of in vitro-translated luciferase was measured by Luciferase 480 
assay kit (Promega, E1960) according to the manufacturer’s instructions. Reporter mRNAs either 481 
presence or absence of poly (A) tails were in vitro transcribed using PCR amplified FLuc-MS2bs 482 
fragment with following primers; 5′-483 
GACTAGTAATACGACTCACTATAGGGGCCACCATGGAAGACGCCAAAAACATAAAG-3′ (sense) 484 
and 5′-TCTAGACCCCGGGAGCATGGGTGAT-3′ (antisense) for the FLuc-MS2bs Poly (A)- mRNA, 485 
and 5′-GACTAGTAATACGACTCACTATAGGGGCCACCATGGAAGACGCCAAAAACATAAAG-3′ 486 
(sense) and 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCTAGACCCCGGGAGCATGGGTGAT-3′ 487 
(antisense) for the FLuc-MS2bs Poly (A)+ mRNAs. 488 
 489 
RNA Isolation and qRT-PCR 490 
The details of RNA isolation and qRT-PCR assays are as described previously2. In brief, RNA was 491 
extracted from cells, co-immunoprecipitation or sucrose gradient fractionation samples using Trizol 492 
(Invitrogen) following the manufacturer’s instructions. qRT-PCR analyses were performed using SYBR 493 
Green PCR Master Mix with the Step One Real-Time PCR System (AppliedBiosystems). All primers 494 
used in this study are listed in Table S2. For the analysis of global or individual mRNA lifetime, 495 
METTL3-depleted or control HeLa cells (60-mm culture dishes) were treated with Actinomycin D (5 496 
µg/ml), then harvested at 0h, 2h, 4h, and 6h.  497 
 498 
Luciferase assay and translation efficiency  499 
Dual luciferase assays were performed according to the manufacturer’s protocol (Promega). Firefly 500 
luciferase (FLuc) activity was normalized to the Renilla luciferase (RLuc) activity. Relative FLuc 501 
activity was normalized to the relative FLuc mRNAs. The normalized FLuc activity (translation 502 
efficiency) in the presence of FLAG-MS2 was set to 1. 503 
 504 
Polysome Fractionation and RNA-seq 505 
METTL3-depleted or control HeLa cells (four 150-mm culture dishes) were treated with 100 µg/ml 506 
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cycloheximide (Sigma) for 10 min at 37°C. Cells were then lysed and layered onto 10%–50% sucrose 507 
gradient tube and centrifuged at 36,000 rpm in a Beckman SW-41Ti rotor for 2.5 hr at 4°C. Gradients 508 
were fractionated and monitored at absorbance 254 nm (Brandel). Collected fractions were pulled into 509 
sub-polysome fraction and polysome fraction. Then, total RNA, sub-polysome and polysome samples 510 
were subjected to RNA-seq. Poly-A selected mRNAs were purified and used for library construction 511 
using TruSeq Stranded mRNA Sample Prep Kits (Illumina RS-122-2101) and sequenced with Illumina 512 
NextSeq 500. ERCC RNA Spike-In Control Mixes (Ambion) were added into each sample before 513 
constructing the library to normalize the reads.  514 
 515 
Co-immunoprecipitation, Mass spectrometry, and Western Blot 516 
Co-immunoprecipitation (co-IP) and western blot were performed as previously2. Briefly, FLAG-517 
METTL3 expressing HeLa or H1299 cells was harvested and lysed using NET-2 buffer [50 mM Tris-518 
HCl (pH 7.4), 150 mM NaCl, 1 mM phenylmethanesulfonylfluoride, 2 mM benzamidine, 1% NP-40] 519 
then the supernatant was subjected to IP using Anti-Flag M2 Affinity Gel (Sigma-Aldrich). Where 520 
indicated, the affinity elute was subjected to SDS-PAGE followed by either Colloidal Coomassie blue 521 
staining or Western blotting. Bands were excised and subjected to Mass spectrometric sequencing as 522 
previously2. The following antibodies were used for Western blotting: METTL3 (Proteintech, 15073-1-523 
AP; Abcam, ab195352), β-actin (Abcam, ab8227), eIF3h (Abcam, ab60942) CBP80 (Gift from Dr. 524 
Yoon Ki Kim, Korea University), CTIF (Gift from Dr. Yoon Ki Kim, Korea University), eIF4E (Cell 525 
Signaling Technology, #2067), eIF3b (Santa Cruz Biotechnology,sc-16377), eIF4GI (Cell Signaling 526 
Technology, #2498), FLAG (Sigma, A8592), BRD4 (Abcam, ab128874), CD9 (Cell Signaling 527 
Technology, #13174), MGMT (Cell Signaling Technology, #2739), TIMP1 (Cell Signaling Technology, 528 
#8946) and FTO (Phosphosolution, 597-FTO). 529 
 530 
Protein Expression, Purification, and GST Pull-Down Assay. 531 
Plasmids expressing the recombinant proteins were transformed into BL21 Escherichia coli then the 532 
recombinant proteins were induced by IPTG at 20 °C overnight. The bacteria were pelleted and 533 
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resuspended in protease inhibitor containing PBST buffer and then lysed by sonication. His-tag 534 
recombinant proteins were purified using Ni-NTA agarose (Qiagen 30210). The GST-tagged proteins 535 
were purified using the glutathione sepharose (BioVision 6655) following the manufacturer’s protocol. 536 
For GST pull down assay, equal amount of GST fusion proteins or GST control bound to glutathione 537 
sepharose were incubated with purified recombinant His-tagged METTL3 full length or N-terminal (1-538 
200) fragment for 1 hour at 4 °C, after extensive washing, the proteins bound to the sepharose were 539 
resolved on SDS–polyacrylamide gels and detected by western blot analysis. 540 
 541 
Far-Western Blotting 542 
Far western blotting was performed with biochemically purified human eIF3 protein complex that was 543 
resolved by SDS-PAGE and then transferred to Hybond ECL nitrocellulose membrane. The 544 
membrane was first incubated in blocking buffer (100 mM Tris (pH 7.5), 100 mM potassium acetate, 2 545 
mM magnesium acetate, 0.1 mM EDTA, 10% glycerol, 1 mM PMSF, 1 mM benzamidine, and 0.05% 546 
Tween 20, 5% non-fat milk) at 4 °C overnight, then the membrane was incubated with blocking buffer 547 
containing 5 μg of purified recombinant METTL3 full-length or METTL3 (1-200) proteins at 4 °C for 548 
another 24 hours. After that, the membrane was incubated with METTL3 antibody for Western blotting 549 
analysis. 550 
 551 
Electron Microscopy 552 
FLAG-METTL3 expressing H1299 cells were harvested and lysed using NET-2 buffer, then the 553 
supernatant was subjected to IP using Anti-Flag M2 Affinity Gel (Sigma-Aldrich). Resin-bound mRNP 554 
complexes were eluted using 3XFLAG peptides (Sigma, F3290). Where indicated, during the elution, 555 
α-METTL3 antibody (Proteintech, 15073-1-AP) and gold nanoparticle (6nm) conjugated α-rabbit IgG 556 
were added with/without either α-CBP80 antibody or α-eIF4E antibody that was gold nanoparticle 557 
(10nm) conjugated using GOLD conjugation kit (Abcam, ab201808) according to the manufacturer’s 558 
instructions. The elutes were then fractionated using 10%-50% sucrose gradients. Each fraction was 559 
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applied to an EM grid (EMS, G400-Cu) covered with a thin layer of carbon and after 1 min the excess 560 
suspension was sucked up with a filter paper. The grid was washed twice with water and 0.7% uranyl 561 
formate, and then negatively stained for 20 seconds with 0.7% uranyl formate. The specimens were 562 
examined in Tecnai G2 Spirit BioTWIN Transmission Electron Microscope (FEI company) with AMT 2k 563 
CCD camera equipped. Direct magnification of 68,000x was used to detect images from Extended 564 
Data Fig. 10a, whereas magnification of 98,000x was used to detect images from Fig. 1b, 3h, 565 
Extended Data Fig. 4a and Extended Data Fig. 4c. Polysome numbers were counted using 20 566 
individual pictures for each sample with direct magnification of 30,000x in Fig. 3f. All the images 567 
shown in the Figures were cropped sections. The average distance between immuno-gold particles in 568 
Extended Data Fig. 4d were measured from the images in Fig. 1b and Extended Data Fig. 4c using 569 
the electron microscope software (AMT Capture engine). In vitro translation reactions were performed 570 
for 1 hour at 30°C using RRL, and then the total reaction mixture was subjected to illustraTM 571 
MicroSpinTM S-400 HR Columns (Figure 3f and Extended Data Fig. 10a) or sucrose gradient 572 
fractionation (Fig. 3g and 3h). The elutes were then applied to an EM grid and analyzed by electron 573 
microscopy.  574 
 575 
Cap-association assay using m7GTP-Agarose 576 
To analyze the interaction of METTL3 to cap-binding protein complex, cells were lysed using NET2 577 
buffer and total cell extracts were incubated with m7GTP-Agarose (Jena Bioscience, AC-155S) for 2 578 
hours at 4°C. Then, the beads were washed for five times and suspended in SDS sample buffer. The 579 
eluted samples were analyzed by Western blot. Where indicated, 75 µM of m7G(5’)ppp(5’)G Cap 580 
Analog (Ambion, AM8048) was added into the sample and incubated with m7GTP-Agarose. 581 
 582 
Cell Proliferation and Apoptosis Assays 583 
Cell proliferation and apoptosis assays were performed as described2. Briefly, for cell proliferation, 584 
700 cells were seeded in a 96-well plate on day 0 with the pertinent treatment. 500 nM of JQ1 were 585 
used. Absorbances at 490 nm were measured using CellTiter 96 AQueous One Solution Cell 586 
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Proliferation Assay kit (Promega) on day 2, day 4, and day 6 to measure the cellular proliferation. The 587 
numbers of apoptotic cells were quantified by flow cytometric assays using Annexin V-FITC Apoptosis 588 
Detection Kit (BioVision) five days after 500 nM of JQ1 treatment and cell seeding. 589 
 590 
Soft Agar Colony Formation Assays 591 
NIH-3T3, MEFs and MB352 cells at 30% confluence were infected with the lentivirus expressing 592 
indicated protein for 48 h in the presence of 8 μg/ml polybrene (Sigma). Two days after infection, 593 
puromycin was added to the media at 2.5 μg/ml, and cells were selected for 1 week. Selected 50,000 594 
live NIH-3T3 cells, 100,000 live MEFs, or 100,000 live MB352  (p53 null MEFs) cells were mixed with 595 
0.35% top-agar and were plated onto 0.6% base-agar in six-well plates. 25 days (NIH-3T3) or 30 days 596 
(MEFS or MB352) after plating the cells into soft agar, colony numbers were counted. The colony 597 
numbers were counted by openCFU. 598 
 599 
In situ Proximity ligation assay (PLA) 600 
HeLa Cells were incubated with primary antibodies (rabbit α-METTL3 antibody and mouse α-eIF3h 601 
antibody) in blocking solution at 4°C for 2 h. Cells were then washed for five times for 5min in PBS 602 
plus 0.1% Tween 20. Then, cells were incubated with secondary proximity probes (α-Rabbit-PLUS 603 
and α-Mouse-MINUS) (Sigma, DUO92101) for 90 min at 37 °C. Cells were washed five times for 5  604 
min in 10 mM Tris-HCl (pH 7.5) plus 0.1% Tween 20 at 37 °C, then twice for 5 min in PBS plus 0.1% 605 
Tween 20. All subsequent steps were performed according to the manufacturer’s instruction. Cells 606 
were observed with a Zeiss LSM 710 Multiphoton Laser Scanning Confocal. 607 
 608 
Immunohistochemistry (IHC) staining 609 
The human lung cancer tumor array was purchased from Biomax (HLug-Ade150CS-01). Slide was 610 
baked for 60 minutes in an oven set to 60°C and then loaded into the Bond III staining platform with 611 
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appropriate labels. Antigen was retrieved by Bond Epitope Retrieval 2 for 20 minutes.  Then the slide 612 
was incubated with METLL3 antibody (Abcam, ab195352) at 1:500 for 30 minutes at RT. Primary 613 
antibody was detected using Bond Polymer Refine Detection kit. Slides were developed in DAB then 614 
dehydrated and coverslipped. Each sample was score by the percentage of positive stained cells 615 
(percentage score: 1-5) and the staining intensity (intensity score: 1-5). Then the sample staining 616 
score was calculated by multiplying the percentage score and the intensity score.   617 
 618 
In vivo tumor xenograft  619 
All research involving animals was complied with protocols approved by the Beth Israel Deaconess 620 
Medical Center Institutional Animal Care and Use Committee. 4-6 weeks old female NU/J (Nude) 621 
immunodeficient mice (Jackson Laboratory #002019) were used for subcutaneous injections. 622 
Randomly divided 5 mice (A549 cells) or 8 mice (NIH-3T3 cells) were used for each group. 100,000 623 
A549 cells or 1,500,000 NIH-3T3 cells in serum-free medium and growth factor reduced Matrigel 624 
(Corning #354230) (1:1) were inoculated into the flank of nude mice. The xenograft tumor formation 625 
was monitored by calipers twice a week. The recipient mice were monitored and euthanized when the 626 
tumors reached 1 cm in diameter. The tumor volume was calculated by use of a formula 1/2 (length X 627 
width2). The investigator was blinded to group allocation. 628 
 629 
m6A MeRIP-Seq and Data Analysis 630 
Performed as previously described2. All the studies involving human patient samples were complied 631 
with protocols approved by Institutional Review Board (IRB). Informed consent was obtained from all 632 
participants. Portions of fresh tumor tissue approximately 0.5 x 0.5 x 0.5cm were snap frozen and 633 
preserved at -80C, pulverized in liquid nitrogen and stabilized in Trizol for total RNA isolation. Then 634 
the mRNA purification from total RNA was performed using PolyATtract mRNA Isolation Systems 635 
(Promega). 2μg of the purified mRNA was fragmented and immunoprecipitated with α-m6A antibody 636 
(Synaptic Systems, 202003). The purified RNA fragments from m6A MeRIP were used for library 637 
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construction using the TruSeq Stranded mRNA Sample Prep Kits (Illumina RS-122-2101) and 638 
sequenced with Illumina NextSeq 500. Reads mapping, peak calling, metagene analysis and motif 639 
search were performed as previously2. To identify the alternative splicing events, all the clean RNA-640 
Seq reads of control and METTL3 knockdown samples were firstly trimmed to same length with 72 641 
bp, which were then aligned against the human hg19 (GRCh37) reference genome using Tophat224. 642 
rMATS v3.2.525 was used to detect the splicing events and significant splicing differences between 643 
METTL3 knockdown and control samples. To analyze the global profiling of mRNA lifetime, the clean 644 
reads were aligned to human reference genome (hg19) using Tophat224 after trimming the adapters 645 
and filtering low quality sequences from the raw data. The reads mapped to each gene were counted 646 
using HTSeq26 based on the GENCODE gene model (v19)27. The raw counts were then normalized 647 
as Reads per kilobase per million mapped reads (RPKM). ERCC RNA Spike-In Control Mixes 648 
(Ambion) were added into each sample before constructing the library to normalize the reads. mRNA 649 
lifetime was calculated according to the method in the previous study8. To analyze METTL3 or eIF3h 650 
expression level among TCGA tumors, RNA-Seq data for 33 TCGA tumor types were downloaded 651 
from Genomic Data Commons Data Portal (GDC) of TCGA (http://cancergenome.nih.gov/) using R 652 
package TCGAbiolinks28 The expression matrix was then constructed by merging the TPM 653 
(Transcripts Per Million) values of all downloaded RNA-seq samples. The tumor types without 654 
corresponding normal tissue samples were excluded and the retained 24 tumor types with normal 655 
tissues were used to draw the boxplot of gene expression. p-values are calculated by Wilcoxon rank-656 
sum test, with asterisks indicating statistical significance.  657 
 658 
Statistics and Reproducibility 659 
Data are presented as the mean ± SEM or mean ± SD. Statistical significance was determined by a 660 
Student’s two-tailed t-test for qRT-PCRs and Luciferase assays. Where it is applicable, Shapiro-Wilk 661 
test and Q-Q plotting (quantile-quantile plot,) were performed prior to Student’s two-tailed t-test to 662 
assess if the data plausibly came from a normal distribution. Where indicated, Shapiro-Wilk signed-663 
rank test was used. P<0.05 was considered statistically significant. Sample size for Extended Data Fig. 664 
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10a-b;  n = 408, n = 1,095, n = 304, n = 36, n = 285, n = 184, n = 155, n = 520, n = 66, n = 533, n = 665 
290, n = 371, n = 515, n = 501, n = 178, n = 179, n = 497, n = 94, n =259, n = 103, n = 415, n = 505, n 666 
= 120 and n = 176, from the order of left to right for TP; n = 19, n = 133, n = 3, n = 9, n = 41, n = 11, n 667 
= 5, n = 44, n = 25, n = 72, n = 32, n = 50, n = 59, n = 51, n = 4, n = 3, n = 52, n = 10, n = 2, n =1, n = 668 
35, n = 59, n = 2 and n = 24, from the order of left to right for NT. Sample size for Extended Data Fig. 669 
10c;  n = 285, n = 184, n = 155, n = 371, n = 515, n = 501, n = 497 and n = 94, from the order of left to 670 
right. 671 
 672 
Code availability  673 
Script and code used for data analysis can be found at [https://github.com/rnabioinfor/rnamethy]. 674 
 675 
Data availability 676 
The m6A MeRIP-Seq and RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) 677 
under accession number GSE117299. 678 
 679 
Extended Data Fig. 1 | METTL3 binding close to the stop codon enhances translation. a, 680 
Schematic diagram of reporter plasmids containing Firefly luciferase cDNA and different positions of 681 
MS2 binding sites. b, Western blotting with indicated antibodies. Two independently performed 682 
experiments show similar results. c, qRT-PCR analysis of reporter mRNAs. Each tested reporter 683 
mRNAs were normalized to RLuc mRNAs. The FLuc:RLuc ratio for each construct with FLAG-MS2 684 
expression was set to 1. Error bars represent mean ± SD; n = 3 biologically independent samples. d, 685 
Tethering assay to measure translation efficiency as described in (Fig. 1h). Error bars represent 686 
mean ± SD; n = 3 biologically independent samples; two-sided t-test. e, Colloidal Coomassie blue 687 
staining of recombinant protein His-FLAG-MS2, His-FLAG-MS2-METTL3, or His-FLAG-MS2-METTL3 688 
(1-200). Two independently performed experiments show similar results. f, Ethidium bromide-stained 689 
agarose gel electrophoresis of the indicated in vitro transcribed reporter mRNAs; FLuc-MS2bs without 690 
poly (A) tail (Poly (A) -) or FLuc-MS2bs with 30nt poly (A) tail (Poly (A) +). Two independently 691 
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performed experiments show similar results. g, In vitro translation of reporter mRNAs using either 692 
H1299 cell extracts or Rabbit reticulocyte lysate (RRL). The levels of in vitro-translated FLuc protein 693 
were analyzed using luciferase assays. Value of FLuc activity in the presence of His-FLAG-MS2 694 
recombinant protein was set to 1.0. Error bars represent mean ± SD; n = 6 independent experiments. 695 
Two-sided t-test, *** denotes multiple comparison for the p-values showing P < 0.001. 696 
 697 
Extended Data Fig. 2 | N-terminal region of METTL3 promotes translation. a, Schematic diagram 698 
of METTL3 deletion mutants or mutation in METTL3 catalytic domain. b, Western blotting with 699 
indicated antibodies. Two independently performed experiments show similar results. c, qRT-PCR 700 
analysis of reporter mRNAs. FLuc-MS2bs mRNA levels were normalized to RLuc mRNAs. The 701 
FLuc:RLuc ratio obtained in FLAG-MS2 (control) was set to 1. Error bars represent mean ± SD; n = 3 702 
biologically independent samples. d, Tethering assay to measure translation efficiency of reporter 703 
mRNAs as described in (Fig. 1 h). Error bars represent mean ± SD; n = 3 biologically independent 704 
samples. Two-sided t-test, ** denotes multiple comparison for the p-values showing P < 0.01.  705 
 706 
Extended Data Fig. 3 | METTL3 associates with translation initiation factors. a, Deletion mutants 707 
of METTL3 were expressed in HeLa cell. The total-cell extracts (Input) and the cap-associated protein 708 
samples were analyzed by Western blotting using the indicated antibodies. Two independently 709 
performed experiments show similar results. b, Cap-association assay with METTL3 depletion. The 710 
total-cell extracts (Input) and the cap-bound protein samples were analyzed by Western blotting using 711 
the indicated antibodies. m7GpppG cap analogue was used for antagonizing cap-associating proteins 712 
binding to m7GTP-Agarose. Two independently performed experiments show similar results. c, Same 713 
as (b) except HeLa cells were transfected with CTIF, eIF3b or eIF4GI siRNA. Two independently 714 
performed experiments show similar results. d-f, Mass spectrometry of FLAG-METTL3 interacting 715 
proteins. d, Proteins that were co-immunopurified with FLAG-METTL3 subjected to 4-12% Tris-716 
Glycine SDS-PAGE. Colloidal Coomassie blue staining was performed. n=1 independent experiment. 717 
e, Gene ontology analysis of the identified proteins from Mass spectrometry. n=1 independent 718 
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experiment. Hypergeometric distribution (one-tail) with Bonferroni adjustment was used to determine 719 
enrichment statistical significance. f, Table showing the translation involving factors identified from 720 
Mass spectrometry. 721 
 722 
Extended Data Fig. 4 | N-terminal region of METTL3 directly interacts with MPN domain of 723 
eIF3h. a, EM images of polyribosome with METTL3-gold particle labeling. Red arrows indicate 724 
METTL3 with immuno-gold particle (6 nm). Three independently performed experiments show similar 725 
results.  b, Counting of METTL3 with gold particle labeling in each polyribosome. c, EM images of 726 
polyribosome with METTL3 and eIF4E. Red arrows indicate METTL3 with immuno-gold particle (6 727 
nm) and yellow arrows indicate eIF4E with immuno-gold particle (10 nm). Four independently 728 
performed experiments show similar results.  d, Average distance between immuno-gold particles 729 
was measured. n = 6 biologically independent samples from at least three independent experiments. 730 
Error bars represent mean ± SD. e, Colloidal Coomassie blue staining of recombinant protein His-731 
METTL3 or His-METTL3 1-200 amino acid fragments (1-200). Two independently performed 732 
experiments show similar results. f, Colloidal Coomassie blue staining of recombinant GST-tagged 733 
protein eIF3g, eIF3h, eIF3i, eIF3j or eIF3m. Two independently performed experiments show similar 734 
results. g, GST-eIF3h was co-purified with His-METTL3 in the presence of either rabbit IgG (rIgG) or 735 
α-METTL3 antibody. Levels of co-purified His-METTL3 were analyzed by Western blotting. Two 736 
independently performed experiments show similar results. h, Schematic diagram of human eIF3h 737 
deletion mutants. i, Colloidal Coomassie blue staining of recombinant GST-eIF3h, -eIF3h (1-222) or -738 
eIF3h (29-222). n = 1 independent experiments. j, GST pull-down of indicated eIF3h deletion mutants. 739 
Co-purified His-METTL3 was analyzed by Western blotting. n = 1 independent experiments. k, 740 
Western blotting demonstrates efficient knockdown of eIF3h protein. Three independently performed 741 
experiments show similar results. l, qRT-PCR analysis demonstrates efficient down regulation of 742 
eIF3h mRNA. Error bars represent mean ± SD; n = 3 biologically independent samples; two-sided t-743 
test. m, qRT-PCR analysis of reporter mRNAs. FLuc-MS2bs reporter mRNAs were normalized to 744 
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RLuc mRNAs. The FLuc:RLuc ratio obtained in FLAG-MS2 was set to 1. Error bars represent mean ± 745 
SD; n = 3 biologically independent samples. 746 
 747 
Extended Data Fig. 5 | METTL3 has no significant effect on mRNA stability. a, Western blotting 748 
with indicated antibodies. Three independently performed experiments show similar results. b, Gene 749 
ontology analysis of the overlapping mRNAs (n=809) in (Fig. 2d). Hypergeometric distribution (one-750 
tail) with Bonferroni adjustment was used to determine enrichment statistical significance. c, qRT-751 
PCR analysis using indicated primers. Error bars represent mean ± SD; n = 3 technical replicates.   d-752 
e, Half-life of endogenous mRNAs was analyzed by qRT-PCR using indicated primers. Error bars 753 
represent mean ± SEM; n = 6 independent experiments. For (d), two-sided t-test; multiple comparison 754 
for the p-values showed that there were no significant differences between the samples for all the 755 
tested mRNAs, P > 0.05. 756 
 757 
Extended Data Fig. 6 | Widespread role of METTL3 in oncogene translation. a, IP of endogenous 758 
METTL3 and Western blotting analysis using indicated antibodies. Two independently performed 759 
experiments show similar results. b, Density plot reflects the distribution of changes in percent spliced 760 
In (∆PSI) values and according p-values for alternative splicing events detected by rMATs v3.2.5 761 
(rMATs is developed based on a hierarchical framework and likelihood-ratio test was used to detect 762 
differential splicing). Splicing events at a FDR < 5% and deltaPSI > 0.1 are considered as significant. 763 
Black dots indicate total mRNAs. Red dots (4,276 mRNAs) indicate more than 2-fold less translating 764 
mRNAs in METTL3 depleted cells. c, Western blot using indicated antibodies in control-, METTL3- or 765 
YTHDF1-knockdwon cells. Two independently performed experiments show similar results. d, qRT-766 
PCR analysis of endogenous BRD4 mRNAs. Error bars represent mean ± SEM; n = 3 biologically 767 
independent samples.  e, Annexin V/PI staining of METTL3 knockdown and control A549 cells upon 768 
JQ1 treatment that was analyzed by FACS. n = 3 independent experiments. 769 
 770 
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Extended Data Fig. 7 | Identification of a conserved Alanine residue in the N-terminal region of 771 
METTL3 required for its interaction with eIF3h. a, Secondary structure prediction of the N-terminal 772 
(1-200) region of METTL3 protein showing putative alpha helices (blue lines). b, Evolutionary 773 
conservation of the N-terminal (1-200) region METTL3 protein. c, Computational modeling of the 3D 774 
structure of the N-terminal (77-163) region METTL3 protein, based on the coordinates of PDB: 3HHH. 775 
d, Western blotting analysis using indicated antibodies. Two independently performed experiments 776 
show similar results. e, qRT-PCR analysis of reporter mRNAs. FLuc-MS2bs mRNA levels were 777 
normalized to RLuc mRNAs. The FLuc:RLuc ratio obtained in FLAG-MS2 (control) was set to 1. Error 778 
bars represent mean ± SD; n = 6 independent experiments. f, IP of FLAG-METTL3 WT or A155P and 779 
Western blotting analysis using indicated antibodies. Two independently performed experiments show 780 
similar results. g, Staining of recombinant protein His-FLAG-MS2-METTL3 WT or His-FLAG-MS2-781 
METTL3 A155P. Two independently performed experiments show similar results.  782 
 783 
Extended Data Fig. 8 | a, Representative staining image of control and different stages lung cancer 784 
samples (n=75). Lower panels show the enlarged sections of the upper ones. Scale bar=30µM. b, 785 
Western blotting analysis using indicated antibodies. n = 1 independent experiments. c-d, Tumor 786 
images (c) and plot of tumor weight (d) at the endpoint in the xenograft experiment. Error bars 787 
represent mean ± SEM; n = 5 independent mice; two-sided t-test. e-h, Western blotting analysis using 788 
indicated antibodies. For (e), two independently performed experiments show similar results.  For (f-h), 789 
n = 1 independent experiments. i, Tumor images at the endpoint in the xenograft experiment. Scale 790 
bar, 20mm. j, Overlapping of m6A containing genes identified in four lung cancer patient samples. k, 791 
Distribution of m6A sites. 792 
 793 
Extended Data Fig. 9 | a, EM images of polyribosomes. Images were taken from the samples in (Fig. 794 
3e). Scale bar, 50 nm. Six independently performed experiments show similar results. b, Gene 795 
ontology analysis. Common methylated genes refers to the methylated genes in all four patient 796 
samples. Not methylated genes refers to the genes not methylated in any of the four patient samples. 797 
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Hypergeometric distribution (one-tail) with Bonferroni adjustment was used to determine enrichment 798 
statistical significance. c, Venn Diagram showing m6A peak overlap between patient tumor samples 799 
and cells (H1299 and A549). 800 
 801 
Extended Data Fig. 10 | a, METTL3 gene expression among TCGA tumors. Box plots display the full 802 
range of variation based on the five number summaries (minimum, first quartile, median, third quartile, 803 
and maximum). TP= primary solid tumor, NT= solid tissue normal. Two-sided Wilcoxon signed-rank 804 
test was used for statistical significance. b, eIF3h gene expression among TCGA tumors. Box plots 805 
display the full range of variation based on the five number summaries (minimum, first quartile, 806 
median, third quartile, and maximum). TP= primary solid tumor, NT= solid tissue normal. Two-sided 807 
Wilcoxon signed-rank test was used for statistical significance. c, Plot illustrating the Pearson’s 808 
correlations of expression level between METTL3 and eIF3h in eight TCGA tumors, in which both 809 
METTL3 and eIF3h are significantly changed compared with normal tissues. 810 
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